Pharming Group N.V annual current ratio
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Current Ratio Growth & History (PHAR)
Pharming Group N.V's current ratio was 2.59 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.59 | −1.19 | −31.45% |
| 2024 | 2024-12-31 | 3.77 | −0.28 | −7.01% |
| 2023 | 2023-12-31 | 4.06 | −0.59 | −12.72% |
| 2022 | 2022-12-31 | 4.65 | −0.68 | −12.84% |
| 2021 | 2021-12-31 | 5.33 | 1.91 | +55.71% |
| 2020 | 2020-12-31 | 3.43 | 2.38 | +227.65% |
| 2019 | 2019-12-31 | 1.05 | — | — |
Pharming Group N.V quarterly current ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.01 | 0.22 | +7.71% |
| Q1 2026 | 2026-03-31 | 2.63 | — | — |
| Q4 2025 | 2025-12-31 | 2.59 | −1.19 | −31.45% |
| Q3 2025 | 2025-09-30 | 3.16 | — | — |
| Q2 2025 | 2025-06-30 | 2.79 | — | — |
| Q4 2024 | 2024-12-31 | 3.77 | −0.28 | −7.01% |
| Q4 2023 | 2023-12-31 | 4.06 | −0.59 | −12.72% |
| Q4 2022 | 2022-12-31 | 4.65 | −0.68 | −12.84% |
| Q4 2021 | 2021-12-31 | 5.33 | 1.91 | +55.71% |
| Q4 2020 | 2020-12-31 | 3.43 | — | — |
Pharming Group N.V current ratio trends
Over the last five fiscal years, Pharming Group N.V's current ratio decreased from 3.43 to 2.59, a change of −0.84. The latest reported quarter, Q2 2026, shows 3.01.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...